Danaher Corporation (NYSE:DHR) and AstraZeneca PLC (NASDAQ:AZN) have announced a major partnership to accelerate the ...

DHR and AstraZeneca team up to develop AI-powered diagnostics, aiming to boost precision medicine by improving patient ...

The focus will initially be on creating computational and digital pathology products, as well as AI-assisted algorithms.

Danaher Corporation, a key player in Life Sciences, Biotechnology, and Diagnostics, has shown mixed financial performance with recent declines in revenue and net earnings. Despite recent struggles ...

Danaher Corp. engages in the design, manufacture, and marketing of professional, medical, industrial, and commercial products and services. It operates through the following segments ...

Danaher Corporation incorporates science and technology and has a market cap of $150B. The company has mixed financials, with its gross profit margin being its strongest and most consistent.

Danaher Corporation beats earnings expectations. Reported EPS is $2.02, expectations were $1.84. Operator: Good morning. My name is Todd, and I will be your conference facilitator today.

The industry as a whole closed the day down 0.2%. By the end of trading, Danaher Corporation fell $1.02 (-1.6%) to $63.68 on average volume. Throughout the day, 3,164,346 shares of Danaher ...

About a year ago, Danaher Corporation's (NYSE: DHR) valuation looked cheap relative to its peers. Of course, when I write peers, I mean its medical, life sciences, and diagnostics peers because ...

Danaher Corporation was a leading decliner within the industrial industry, falling $2.65 (-4.7%) to $53.45 on heavy volume. Editor's Note: TheStreet ratings do not represent the views of TheStreet ...

Danaher Corporation (NYSE:DHR) Executive Vice President Julie Sawyer Montgomery highlighted the goal of increasing access to precision medicines so that no patients are left behind, while ...